ダウンロード数: 262
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
38_1305.pdf | 345.22 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | 中野, 悦次 | ja |
dc.contributor.alternative | Nakano, Etsuji | en |
dc.date.accessioned | 2010-06-01T02:57:03Z | - |
dc.date.available | 2010-06-01T02:57:03Z | - |
dc.date.issued | 1992-11 | - |
dc.identifier.issn | 0018-1994 | - |
dc.identifier.uri | http://hdl.handle.net/2433/117693 | - |
dc.description.abstract | 腎摘除術時すでに転移巣をもつ9例を含む, 15例にLAK細胞を週一度, IL-2毎日と併用で治療した。肺転移の10例のうち4例に部分反応(PR)がみられ, 腫瘍の縮小がみられる。副作用として頭痛, 悪寒, 戦慄が全例にみられるが経口解熱剤でコントロールできた。IL-2の副作用として, 発熱, 浮腫, 好酸菌増多があった。PR 4例中1例は脳転移で死亡したが, 3例は生存中である。脳転移はNC・PDの例も含めて施行を合わせると脳転移が4例と多い | ja |
dc.description.abstract | Fifteen patients with metastatic renal cell carcinoma (RCC) were treated by administration of autologous lymphokine-activated killer (LAK) cells given together with systemic administration of interleukin-2 (IL-2). Pulmonary metastases alone were found in 10 cases, pulmonary and mediastinal nodal metastases in 3, and pulmonary and bone metastases in 2. LAK cells, generated by incubation in 700 units/ml of IL-2 for 3-4 days, were intravenously administered once a week. In addition, beginning on the day of the first LAK cell infusion, 3.5 x 10(5) units of IL-2 were intravenously infused once or twice a day with occasional supplementation of 3.5 x 10(5) units of IL-2 on each day of LAK cell infusion. The total number of LAK cells and total amount of IL-2 administered per patient in this study ranged from 0.8 x 10(10) to 6.9 x 10(10) cells and from 10.2 x 10(6) to 74.9 x 10(6) units, respectively. As toxic effects caused by the infusion of LAK cells, headache, shaking chills, fever and leukocytosis were found in all cases. Side effects possibly induced by IL-2 infusion were tolerable fever, fluid retention (body weight gain of 2-3 kg) and eosinophilia. Out of 15 patients, a partial response was observed in 4 patients who had pulmonary metastases alone. One of the 4 patients with a partial response was clinically free of disease after undergoing a thoracotomy for resection of residual lesions, but a brain metastasis was detected 10 months after the thoracotomy. The remaining 3 patients are being closely followed up at present.(ABSTRACT TRUNCATED AT 250 WORDS) | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | jpn | - |
dc.publisher | 泌尿器科紀要刊行会 | ja |
dc.subject | Renal cell carcinoma | en |
dc.subject | Interleukin-2 | en |
dc.subject | Lymphokine-activated killer cells | en |
dc.subject.ndc | 494.9 | - |
dc.title | 進行腎癌に対するLAK(Lymphokine-Activated Killer)療法 | ja |
dc.title.alternative | Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma | en |
dc.type | departmental bulletin paper | - |
dc.type.niitype | Departmental Bulletin Paper | - |
dc.identifier.ncid | AN00208315 | - |
dc.identifier.jtitle | 泌尿器科紀要 | ja |
dc.identifier.volume | 38 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 1305 | - |
dc.identifier.epage | 1309 | - |
dc.textversion | publisher | - |
dc.sortkey | 19 | - |
dc.address | 大阪大学医学部泌尿器科学教室 | ja |
dc.address.alternative | the Department of Urology, Osaka University Medical School | en |
dc.identifier.pmid | 1485586 | - |
dcterms.accessRights | open access | - |
dc.identifier.pissn | 0018-1994 | - |
dc.identifier.jtitle-alternative | Acta urologica Japonica | la |
dc.identifier.jtitle-alternative | Hinyokika Kiyo | en |
出現コレクション: | Vol.38 No.11 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。